Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (5581)	2/1/2002 3:44:40 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 52153

A month ago you posted an article on Biotech IPOs Among the Bay Area's losers, Exelixis closed 28 percent below its IPO opening on Friday. Durect, Genencor, Sangamo BioSciences and Rigel Pharmaceuticals were off between 35 and 45 percent. Kosan Biosciences, Deltagen and Cepheid are worth about half of what investors paid for them initially. Shares in Maxygen and Virologic are roughly 60 percent below what they commanded at their IPO opening. Ciphergen Biosystems, Large Scale Biology and Aclara BioSciences are off more like 80 percent. And today Zymogenetics, ZGEN, came out priced well below where they had intended. Whew, I cannot keep track of them all. But there must be a few keepers in the list; are there any you are watching with great interest Wilder and everybody else? quote.yahoo.com